259 related articles for article (PubMed ID: 20656548)
1. Angiogenin-mediated ribosomal RNA transcription as a molecular target for treatment of head and neck squamous cell carcinoma.
Chen L; Hu GF
Oral Oncol; 2010 Sep; 46(9):648-53. PubMed ID: 20656548
[TBL] [Abstract][Full Text] [Related]
2. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract][Full Text] [Related]
3. [Anti-angiogenesis - a therapy concept in the treatment of head and neck carcinomas? A review].
Riedel F; Hörmann K
Laryngorhinootologie; 2001 Sep; 80(9):535-41. PubMed ID: 11555787
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic, Prognostic, and Therapeutic Role for Angiogenesis Markers in Head and Neck Squamous Cell Carcinoma: A Narrative Review.
Alessandrini L; Astolfi L; Daloiso A; Sbaraglia M; Mondello T; Zanoletti E; Franz L; Marioni G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445908
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.
Liu JF; Deng WW; Chen L; Li YC; Wu L; Ma SR; Zhang WF; Bu LL; Sun ZJ
Mol Carcinog; 2018 Mar; 57(3):429-439. PubMed ID: 29215754
[TBL] [Abstract][Full Text] [Related]
8. Molecular therapy in head and neck oncology.
Bernier J; Bentzen SM; Vermorken JB
Nat Rev Clin Oncol; 2009 May; 6(5):266-77. PubMed ID: 19390553
[TBL] [Abstract][Full Text] [Related]
9. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
Bran B; Bran G; Hörmann K; Riedel F
Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
[TBL] [Abstract][Full Text] [Related]
10. Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma.
Masuda M; Ruan HY; Ito A; Nakashima T; Toh S; Wakasaki T; Yasumatsu R; Kutratomi Y; Komune S; Weinstein IB
Oral Oncol; 2007 Sep; 43(8):785-90. PubMed ID: 17169602
[TBL] [Abstract][Full Text] [Related]
11. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications.
Hasina R; Whipple ME; Martin LE; Kuo WP; Ohno-Machado L; Lingen MW
Lab Invest; 2008 Apr; 88(4):342-53. PubMed ID: 18283272
[TBL] [Abstract][Full Text] [Related]
12. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
Oh SH; Kim WY; Kim JH; Younes MN; El-Naggar AK; Myers JN; Kies M; Cohen P; Khuri F; Hong WK; Lee HY
Clin Cancer Res; 2006 Jan; 12(2):653-61. PubMed ID: 16428512
[TBL] [Abstract][Full Text] [Related]
13. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
Riedel F; Götte K; Li M; Hörmann K; Grandis JR
Int J Oncol; 2003 Sep; 23(3):577-83. PubMed ID: 12888890
[TBL] [Abstract][Full Text] [Related]
14. Neamine inhibits prostate cancer growth by suppressing angiogenin-mediated rRNA transcription.
Ibaragi S; Yoshioka N; Li S; Hu MG; Hirukawa S; Sadow PM; Hu GF
Clin Cancer Res; 2009 Mar; 15(6):1981-8. PubMed ID: 19276260
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck.
Neuchrist C; Erovic BM; Handisurya A; Fischer MB; Steiner GE; Hollemann D; Gedlicka C; Saaristo A; Burian M
Head Neck; 2003 Jun; 25(6):464-74. PubMed ID: 12784238
[TBL] [Abstract][Full Text] [Related]
16. Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma.
Homer JJ; Greenman J; Stafford ND
Clin Otolaryngol Allied Sci; 2002 Feb; 27(1):32-7. PubMed ID: 11903369
[TBL] [Abstract][Full Text] [Related]
17. Angiogenin-stimulated rRNA transcription is essential for initiation and survival of AKT-induced prostate intraepithelial neoplasia.
Ibaragi S; Yoshioka N; Kishikawa H; Hu JK; Sadow PM; Li M; Hu GF
Mol Cancer Res; 2009 Mar; 7(3):415-24. PubMed ID: 19258415
[TBL] [Abstract][Full Text] [Related]
18. The role of antiangiogenic agents in the treatment of head and neck cancer.
Denaro N; Russi EG; Colantonio I; Adamo V; Merlano MC
Oncology; 2012; 83(2):108-16. PubMed ID: 22777379
[TBL] [Abstract][Full Text] [Related]
19. Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review.
Muratori L; La Salvia A; Sperone P; Di Maio M
Crit Rev Oncol Hematol; 2019 Jul; 139():41-52. PubMed ID: 31112881
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
